Christos Kakouratos

Dr. Christos Kakouratos

Barts Cancer Institute, Queen Mary University of London, London, City of London, UK
orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 March 2016 in International Journal of Radiation Biology
Verified
Journal Article
Closed access
PDF file
Michael I. KoukourakisMichael I. Koukourakis
Michael I. Koukourakis
CKChristos Kakouratos
Christos Kakouratos
DKDimitra Kalamida
Dimitra Kalamida
ZBZoi Bampali
Zoi Bampali
SMSophia Mavropoulou
Sophia Mavropoulou
AGAlexandra Giatromanolaki
Alexandra Giatromanolaki
Purpose: To assess whether anaerobic metabolism, proliferation activity and stem cell content are linked with radioresistance in bladder cancer. Materials and methods: Tissue sections from 66 patients with invasive transitional cell bladder cancer treated with hypofractionated accelerated radiotherapy, was immunohistochemically analyzed for the Hypoxia-Inducible Factor 1α (HIF1α) and the anaerobic glycolysis enzyme lactate dehydrogenase 5 (LDH5). Proliferation index (Ki-67) and stem-cell marker (cluster of differentiation CD44, aldehyde dehydrogenase ALDH1) expression was also examined. Results: Both HIF1α and LDH5 expression were linked with high CD44 stem cell population (p = 0.001 and 0.05, respectively), while high Ki-67 proliferation index was linked with nuclear LDH5 expression (p = 0.03) and high histological grade (p = 0.02). A strong significant association of HIF1α (p = 0.0009) and of LDH5 (p < 0.0001) with poor local relapse free survival (LRFS) was noted, which was also confirmed in multivariate analysis. A significant association with overall survival was also noted. Silencing of lactate dehydrogenase LDHA gene in the human RT112 bladder cancer cell line, or exposure to oxamate (LDH activity inhibitor), resulted in strong radio-sensitization. Conclusions: HIF1α and LDH5 are markers of poor outcome in patients with bladder cancer treated with radiotherapy. Blockage of anaerobic metabolism may prove of importance in clinical radiotherapy.

1 November 2019 in Current Urology
Verified
Journal Article
Open access
PDF file
AGAlexandra Giatromanolaki
Alexandra Giatromanolaki
VFVirginia Fasoulaki
Virginia Fasoulaki
DKDimitra Kalamida
Dimitra Kalamida
AMAchilleas Mitrakas
Achilleas Mitrakas
CKChristos Kakouratos
Christos Kakouratos
Michael I. KoukourakisMichael I. Koukourakis
Michael I. Koukourakis
Background: CYP17A1 is involved in the steroidogenesis of dehydroepiandrosterone and androstenedione. CYP17A is a target for the hormonal treatment of prostate cancer (PCa). Objectives: To investigate the role of CYP17A1 as a driver of PCa growth. Materials and Methods: We examined the expression of CYP17A1 and of androgen receptors (AR) in PCa specimens and in PCa cell lines. Results: CYP17A1 was strongly expressed in the cytoplasm of PCa cells (median 50% of cancer cells, range 0-100%). The nuclear AR expression in cancer cells was directly related with CYP17A1 (p < 0.0001, r = 0.51). The hormone dependent 22Rv1 cell line expressed the CYP17A1 and AR protein and mRNA, in contrast to the PC3 and DU145 cell lines (p < 0.0001). Testosterone and dexamethasone induced nuclear expression of AR and this effect was abolished by abiraterone. CYP17A1 levels were not affected by the incubation with testosterone, while abiraterone significantly reduced its expression. Abiraterone reduced the growth rate and migration of testosterone stimulated 22Rv1 cells. Conclusions: CYP17A1 is strongly expressed in half about of human prostate carcinomas, implying an intracellular androgen synthesis by cancer cells. Abiraterone effectively blocked nuclear accumulation of AR and suppressed CYP17A1 expression. CYP17A1 may function as a biomarker to select the best hormonal anticancer therapy

19 August 2021 in Medical Oncology
Verified
Journal Article
Closed access
PDF file
ILIoannis Lamprou
Ioannis Lamprou
ATAvgi Tsolou
Avgi Tsolou
CKChristos Kakouratos
Christos Kakouratos
AMAchilleas G. Mitrakas
Achilleas G. Mitrakas
EXErasmia T. Xanthopoulou
Erasmia T. Xanthopoulou
Michael I. KoukourakisMichael I. Koukourakis
Michael I. Koukourakis

1 January 2017 in Cancer Biology & Medicine
Verified
Journal Article
Open access
PDF file
GAGiatromanolaki Alexandra
Giatromanolaki Alexandra
BKBalaska Konstantina
Balaska Konstantina
KDKalamida Dimitra
Kalamida Dimitra
CKChristos Kakouratos
Christos Kakouratos
SESivridis Efthimios
Sivridis Efthimios
Michael I. KoukourakisMichael I. Koukourakis
Michael I. Koukourakis
Increased expression of YAP1 in prostate cancer correlates with extraprostatic extension

1 April 2018 in Anti-Cancer Drugs
Verified
Journal Article
Closed access
Michael I. KoukourakisMichael I. Koukourakis
Michael I. Koukourakis
CKChristos Kakouratos
Christos Kakouratos
DKDimitra Kalamida
Dimitra Kalamida
Achilleas George MitrakasAchilleas George Mitrakas
Achilleas George Mitrakas
SPStamatia Pouliliou
Stamatia Pouliliou
AGAlexandra Giatromanolaki
Alexandra Giatromanolaki
Apalutamide (ARN-509) is an antiandrogen that binds selectively to androgen receptors (AR) and does not show antagonist-to-agonist switch like bicalutamide. We compared the activity of ARN versus bicalutamide on prostate cancer cell lines. The 22Rv1, PC3, and DU145 cell lines were used to study the effect of ARN and bicalutamide on the expression cytoplasmic/nuclear kinetics of AR, AR-V7 variant, phosphorylated AR, as well as the levels of the AR downstream proteins prostate-specific antigen and TMPRSS2, under exposure to testosterone and/or hypoxia. The effects on autophagic flux (LC3A, p62, TFEB, LAMP2a, cathepsin D) and cell metabolism-related enzymes (hypoxia-inducible factor 1α/2α, BNIP3, carbonic anhydrase 9, LDHA, PDH, PDH-kinase) were also studied. The 22Rv1 cell line responded to testosterone by increasing the nuclear entry of AR, AR-V7, and phosphorylated AR and by increasing the levels of prostate-specific antigen and TMPRSS2. This effect was strongly abrogated by ARN and to a clearly lower extent by bicalutamide at 10 μmol/l, both in normoxia and in hypoxia. ARN had a stronger antiproliferative effect than bicalutamide, which was prominent in the 22Rv1 hormone-responsive cell line, and completely repressed cell proliferation at a concentration of 100 μmol/l. No effect of testosterone or of antiandrogens on autophagy flux, hypoxia-related proteins, or metabolism enzyme levels was noted. The PC3 and DU145 cell lines showed poor expression of the proteins and were not responsive to testosterone. On the basis of in-vitro studies, evidence has been reported that ARN is more potent than bicalutamide in blocking the AR pathway in normoxia and in hypoxia. This reflects a more robust, dose-dependent, repressive effect on cell proliferation.

1 March 2025 in Cancers
Verified
Journal Article
Open access
PDF file
Achilleas George MitrakasAchilleas George Mitrakas
Achilleas George Mitrakas
CKChristos Kakouratos
Christos Kakouratos
ILIoannis Lamprou
Ioannis Lamprou
EXErasmia Xanthopoulou
Erasmia Xanthopoulou
Michael I. KoukourakisMichael I. Koukourakis
Michael I. Koukourakis
Background/Objectives: Non-small cell lung cancer (NSCLC) is a major cause of cancer-related deaths globally. The study focuses on understanding the interplay between genetic mutations, cancer stem cells (CSCs), and the tumor microenvironment (TME) in driving NSCLC progression, resistance to therapies, and relapse. Methods: A systematic search was conducted in PubMed and Scopus databases to identify significant and valuable studies relevant to NSCLC, focusing on genetic mutations, CSCs, and the TME. Articles were selected based on their relevance, methodological severity, date of publication, and scientific soundness related to NSCLC biology and therapeutic strategies. This review synthesized findings from these sources to highlight key mechanisms and potential therapeutic interventions. Results: Mutations in critical genes in KRAS, EGFR, TP53, and other key genes interfere with stem cell regulation, promoting CSC-like behavior, resistance to therapy, and immune evasion. The tumor microenvironment (TME), including immune cells, fibroblasts, and extracellular matrix components, further supports tumor growth and reduction in treatment efficacy. Promising strategies, including CSC targeting, TME modulation, and the development of novel biomarkers, have shown potential in preclinical and clinical studies. Conclusions: The association between genetic alterations, CSCs, the TME, and other cellular pathways—including cell metabolism and immune evasion—plays a crucial role in therapy resistance, highlighting the need for comprehensive treatment strategies. The combination of genomic profiling with TME-targeting therapies could lead to personalized treatment approaches, offering hope for better clinical outcomes and reduced mortality in NSCLC patients.